Pre-analytical stability of FGF23 with the contemporary immunoassays.

FGF23 immunoassays Pre-analytical stability Protease inhibitors

Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 30 01 2019
revised: 28 02 2019
accepted: 28 02 2019
pubmed: 4 3 2019
medline: 14 6 2019
entrez: 4 3 2019
Statut: ppublish

Résumé

Several publications have reported on the pre-analytical stability of fibroblast growth factor 23 (FGF23) and some recommend coating blood collecting tubes with protease inhibitors, in order to prevent degradation. These recommendations are based on observations for a first generation assay for the measurement of intact FGF23. However, if this also applies for the contemporary immunoassays, and at what stage of pre-analysis, is unknown. We reviewed data from these previous reports on the issue of FGF23 stability and complemented these findings with data from novel experiments. We concluded that the contemporary intact FGF23 assays by Immutopics, Kainos, Millipore and DiaSorin do not suffer from immediate loss of FGF23 signal and do not require blood withdrawal in protease inhibitor-coated collecting tubes. Nevertheless, FGF23 concentrations do decline when centrifugation is delayed up to 8 h and prompt centrifugation is therefore advised.

Sections du résumé

BACKGROUND BACKGROUND
Several publications have reported on the pre-analytical stability of fibroblast growth factor 23 (FGF23) and some recommend coating blood collecting tubes with protease inhibitors, in order to prevent degradation. These recommendations are based on observations for a first generation assay for the measurement of intact FGF23. However, if this also applies for the contemporary immunoassays, and at what stage of pre-analysis, is unknown.
METHODS METHODS
We reviewed data from these previous reports on the issue of FGF23 stability and complemented these findings with data from novel experiments.
RESULTS RESULTS
We concluded that the contemporary intact FGF23 assays by Immutopics, Kainos, Millipore and DiaSorin do not suffer from immediate loss of FGF23 signal and do not require blood withdrawal in protease inhibitor-coated collecting tubes. Nevertheless, FGF23 concentrations do decline when centrifugation is delayed up to 8 h and prompt centrifugation is therefore advised.

Identifiants

pubmed: 30826370
pii: S0009-8981(19)30094-4
doi: 10.1016/j.cca.2019.02.032
pii:
doi:

Substances chimiques

FGF23 protein, human 0
Fibroblast Growth Factors 62031-54-3
Fibroblast Growth Factor-23 7Q7P4S7RRE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104-106

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Niek F Dirks (NF)

Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands.

Edward R Smith (ER)

The Royal Melbourne Hospital, Department of Nephrology, Melbourne, Australia; University of Melbourne, Department of Medicine, Melbourne, Australia; Monash University, Department of Renal Medicine, Eastern Health Clinical School, Melbourne, Australia.

Natasja M van Schoor (NM)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, Netherlands.

Marc G Vervloet (MG)

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Nephrology, Amsterdam, Netherlands.

Mariëtte T Ackermans (MT)

Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands.

Robert de Jonge (R)

Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands.

Annemieke C Heijboer (AC)

Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands. Electronic address: a.heijboer@vumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH